atorvastatin has been researched along with Metabolic Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Gilowski, W; Krysiak, R; Okopień, B | 1 |
| An, J; Kim, J; Kim, K; Kong, H; Lee, H; Lee, S; Lee, Y; Song, Y | 1 |
| Deedwania, P; Singh, V | 1 |
| Currier, JS | 1 |
1 review(s) available for atorvastatin and Metabolic Diseases
| Article | Year |
|---|---|
Reducing morbidity and mortality in high risk patients with statins.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Kidney Failure, Chronic; Metabolic Diseases; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2009 |
1 trial(s) available for atorvastatin and Metabolic Diseases
| Article | Year |
|---|---|
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
Topics: Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperprolactinemia; Lipids; Metabolic Diseases; Middle Aged; Prolactin; Risk Factors | 2019 |
4 other study(ies) available for atorvastatin and Metabolic Diseases
| Article | Year |
|---|---|
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism.
Topics: Aged; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Humans; Hypogonadism; Lipids; Male; Metabolic Diseases; Middle Aged; Risk Factors; Testosterone; Treatment Outcome; Uric Acid | 2016 |
Atorvastatin and rosuvastatin improve physiological parameters and alleviate immune dysfunction in metabolic disorders.
Topics: Adipose Tissue; Animals; Atorvastatin; Cytokines; Diet, High-Fat; Epitopes; Glucose; Homeostasis; Immunity; Inflammation Mediators; Lipid Metabolism; Male; Metabolic Diseases; Mice, Inbred C57BL; Organ Size; RNA, Messenger; Rosuvastatin Calcium | 2016 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibrozil; Growth Hormone; Guidelines as Topic; Heptanoic Acids; HIV Infections; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipodystrophy; Metabolic Diseases; Metformin; Nucleosides; Protease Inhibitors; Pyrroles; Reverse Transcriptase Inhibitors; Risk Factors; Thiazoles; Thiazolidinediones | 2000 |